Tumor Biology

, Volume 37, Issue 7, pp 8985–8991 | Cite as

CASP 3 genetic polymorphisms and risk of Hepatocellular carcinoma: a case-control study in a Chinese population

  • Benyuan Deng
  • Fei Liu
  • Limei Luo
  • Yonggang Wei
  • Bo Li
  • Hanteng Yang
Original Article


Caspase (CASP) 3 is an important caspase in the apoptosis pathway and plays an important role in the development and progression of cancer. We hypothesized that genetic variants in CASP 3 may modify individual susceptibility to hepatocellular carcinoma (HCC). Five hundred HCC cases in West China Hospital were selected, and 500 healthy cases with the same gender, age (±5 years), and residence place were selected as control group, with proportion of 1:1. The matrix-assisted laser desorption ionization time-of-flight mass spectrometry method was performed to detect these polymorphisms. Among the 500 cases and 500 controls with DNA samples, the genotyping was successful for the CASP3 polymorphisms (rs6948, rs1049216, and rs12108497) in 486 HCC cases and 495 controls, which were included in the final analyses.The results showed that the genotype frequencies of the CASP3 did not differ significantly between the HCC patients and the control group (P > 0.05). However, when stratifying by age, sex, smoking, drinking, HBV carrier status, and family history of cancer, we found that the variant genotypes (CT + TT) of the CASP3 rs12108497 were associated with a significant increased risk of HCC among smoking individuals (adjusted OR = 2.31, 95 % CI = 1.11–4.79). No significant association was observed between the other two polymorphisms of the CASP3 gene and risk of HCC in any stratification analysis. These results suggest that the CASP3 rs12108497 polymorphism may play a role in the development of HCC among smoking individuals in the Chinese population.


Hepatocellular carcinoma Polymorphism CASP3 Susceptibility 



Hepatocellular carcinoma


Hepatitis B virus


Odds ratio


Confidence interval


Single nucleotide polymorphisms


Hardy–Weinberg equilibrium


Compliance with ethical standards

The study was approved by the Ethics Committee of Sichuan University.

Conflicts of interest


Informed consent

Informed consents were obtained according to the Declaration of Helsinki. A written informed consent was obtained from each subject involved in the study.


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.CrossRefPubMedGoogle Scholar
  3. 3.
    International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans: hepatitis viruses. Lyon: IARC; 1994. p. 182–221.Google Scholar
  4. 4.
    Long XD, Ma Y, Zhou YF, et al. Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population. Hepatology. 2010;52:1301–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Liu F, Wei YG, Luo LM, et al. Genetic variants of p21 and p27 and hepatocellular cancer risk in a Chinese Han population: a case-control study. Int J Cancer. 2013;132:2056–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Clifford RJ, Zhang J, Meerzaman DM, et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology. 2010;52:2034–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem. 2003;88:885–98.CrossRefPubMedGoogle Scholar
  8. 8.
    Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997;22:299–306.CrossRefPubMedGoogle Scholar
  9. 9.
    Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003;22:8543–67.CrossRefPubMedGoogle Scholar
  11. 11.
    Kothakota S, Azuma T, Reinhard C, et al. Caspase 3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science. 1997;278:294–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang JX, Zheng S. Caspase 3 and survivin expression in pediatric neuroblastoma and their roles in apoptosis. Chin Med J. 2004;117:1821–4.PubMedGoogle Scholar
  13. 13.
    Devarajan E, Sahin AA, Chen JS, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002;21:8843–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Isobe N, Onodera H, Mori A, et al. Caspase 3 expression in human gastric carcinoma and its clinical significance. Oncology. 2004;66:201–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Fujikawa K, Shiraki K, Sugimoto K, et al. Reduced expression of ICE/caspase1 and CPP32/caspase3 in human hepatocellular carcinoma. Anticancer Res. 2000;20:1927–32.PubMedGoogle Scholar
  16. 16.
    Son JW, Kang HK, Chae MH, et al. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet. 2006;169:121–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Yan F, He Q, Hu X, et al. Direct regulation of caspase-3 by the transcription factor AP-2α is involved in aspirin-induced apoptosis in MDA-MB-453 breast cancer cells. Mol Med Rep. 2013;7:909–14.PubMedGoogle Scholar
  18. 18.
    Li B, Liu H, Gong F, et al. Molecular epidemiologic correlation analysis between caspase3 gene polymorphism and gastric cancer susceptibility. Cell Biochem Biophys. 2014;70:1647–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhang Z, Yu X, Guo Y, et al. Genetic variant in CASP3 affects promoter activity and risk of esophageal squamous cell carcinoma. Cancer Sci. 2012;103:555–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Chen K, Zhao H, Hu Z, et al. CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2008;14:6343–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Jang JS, Kim KM, Choi JE, et al. Identification of polymorphisms in the Caspase-3 gene and their association with lung cancer risk. Mol Carcinog. 2008;47:383–90.CrossRefPubMedGoogle Scholar
  22. 22.
    Mittal RD, Mittal T, Singh AK, Mandal RK. Association of caspases with an increased prostate cancer risk in north Indian population. DNA Cell Biol. 2012;31:67–73.CrossRefPubMedGoogle Scholar
  23. 23.
    Theodoropoulos GE, Gazouli M, Vaiopoulou A, et al. Polymorphisms of caspase 8 and caspase 9 gene and colorectal cancer susceptibility and prognosis. Int J Colorectal Dis. 2011;26:1113–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis. 2004;9:691–704.CrossRefPubMedGoogle Scholar
  25. 25.
    Kesarwani P, Mandal RK, Maheshwari R, Mittal RD. Influence of caspases 8 and 9 gene promoter polymorphism on prostate cancer susceptibility and early development of hormone refractory prostate cancer. BJU Int. 2011;107:471–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Soung YH, Lee JW, Kim SY, et al. Somatic mutations of CASP3 gene in human cancers. Hum Genet. 2004;115:112–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Kurokawa H, Nishio K, Fukumoto H, et al. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep. 1999;6:33–7.PubMedGoogle Scholar
  28. 28.
    Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.CrossRefPubMedGoogle Scholar
  29. 29.
    Xu HL, Xu WH, Cai Q, et al. Polymorphisms and haplotypes in the caspase-3, caspase-7, and caspase-8 genes and risk for endometrial cancer: a population-based, case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2009;18:2114–22.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ni Q, Jiang X, Jin MJ, et al. Association of CASP3 and CASP9 polymorphisms with genetic susceptibility to stomach cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011;28:318–22.PubMedGoogle Scholar
  31. 31.
    Yan S, Li YZ, Zhu XW, et al. HuGE systematic review and meta-analysis demonstrate association of CASP-3 and CASP-7 genetic polymorphisms with cancer risk. Genet Mol Res. 2013;12:1561–73.CrossRefPubMedGoogle Scholar
  32. 32.
    Marrero JA, Fontana RJ, Fu S, et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;42:218–24.CrossRefPubMedGoogle Scholar
  33. 33.
    Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000;85:498–502.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhu K, Moriarty C, Caplan LS, Levine RS. Cigarette smoking and primary liver cancer: a population-based case-control study in US men. Cancer Causes Control. 2007;18:315–21.CrossRefPubMedGoogle Scholar
  35. 35.
    Tanaka K, Tsuji I, Wakai K, et al. Cigarette smoking and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among Japanese. Jpn J Clin Oncol. 2006;36:445–56.CrossRefPubMedGoogle Scholar
  36. 36.
    International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans: tobacco smoke and involuntary smoking. Lyon: IARC; 2004. p. 161–76.Google Scholar
  37. 37.
    Imaizumi T, Higaki Y, Hara M, et al. Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis. 2009;30:1729–34.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Benyuan Deng
    • 1
  • Fei Liu
    • 1
  • Limei Luo
    • 2
  • Yonggang Wei
    • 1
  • Bo Li
    • 1
  • Hanteng Yang
    • 1
  1. 1.Department of liver surgery & Division of Liver Transplantation, West China HospitalSichuan UniversityChengduChina
  2. 2.Department of Clinical Immunological Laboratory, West China HospitalSichuan UniversityChengduChina

Personalised recommendations